23 Jul 2020

Jerome Groopman writes about the National Emerging Infectious Diseases Laboratories, in Boston, which is taking a cautious and deliberate approach to the study of the coronavirus and possible treatments.

Read the full article here.
This content was originally published by the new yorker business. Original publishers retain all rights. It appears here for a limited time before automated archiving. By the new yorker business

Covid-19 – Johns Hopkins University

Download brochure

Introduction brochure

What we do, case studies and profiles of some of our amazing team.